Эффективность применения инсулина гларгин в условиях реальной клинической практики: результаты наблюдательной программы LAURUS-2
https://doi.org/10.14341/probl201157615-20
Аннотация
Список литературы
1. UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
2. Turner R., Cull C., Frighi V., Holmann R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
3. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Dis 2002; 26: S18-S24.
4. Cryer P., Childs B.P. Negotiating the barrier of hypoglycemia in diabetes. Diabetes Spectrum 2002; 15: 20-27.
5. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46.
6. AACE: The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management: 2000 update. Endocrine Practice 2000; 6: 43-84.
7. A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group 1999. Diabet Med 1999; 16: 716-730.
8. NICE: Clinical guidelines for type 2 diabetes: management of blood glucose [article online], 2002. London: NICE. Available from http://www.nice.org.uk
9. Barnett A. A review of basal insulins. Diabet Med 2003; 20:873-885.
10. Bolli G.B. The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diabet Res Clin Pract 1989; 6: S3-S16.
11. Binder C., Lauritzen T., Faber O., Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-199.
12. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., Cordoni C., Costa E., Brunetti P., Bolli G.B. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
13. Riddle M., Rosenstock J., Gerich J. Investigators IGS: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabet Care 2003; 26: 3080-3086.
14. Rosenstock J., Benedetti M., Haring H.U., Lin Z., Salzman A. Confirmed lower risk of hypoglycemia with insulin glargine versus NPH insulin: a meta-analysis of 2304 patients with type 2 diabetes. Diabetologia 2003; 46: A304.
15. Yki-Järvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: HOE 901/3002 Study Group. Diabet Care 2000; 23: 1130-1136.
16. American Diabetes Association: Clinical Practice Recommendations 2003. Diabet Care 2003; 26: Suppl 1: S1-S156.
17. Davies M., Storms F., Shutler S., Bianchi-Biscay M., Gomis R. Insulin glargine in type 2 patients with suboptimal glycemic control on twice-daily premix insulin: AT. LANTUS Trial Results study (Abstract). Diabetes 2004; 53: Suppl 2: A473.
18. Lavalle-Gonzalez F., Storms F., Shutler S., Bianchi-Biscay M., Gomis R. Effect of basal insulin glargine therapy in type 2 patients inadequately controlled on oral antidiabetic agents: AT.LANTUS trial results. Abstract presented at the American Diabetes Association 64th Scientific Sessions, 4-8 June 2004. The Orange County Convention Center. Orlando (Florida) 2004.
19. Fulcher G., Storms F., Shutler S., Leperlier C., Gomis R., Davies M. Initiation of insulin glargine in patients with type 2 diabetes suboptimally controlled on once- or twice-daily NPH insulin: results from the AT. LANTUS trial. Diabetologia 2004; 47:A272.
20. Lavalle-Gonzalez F., Storms F., Shutler S., Bianchi-Biscay M., Gomis R., Davies M. Initiation of basal insulin glargine therapy in type 2 patients inadequately controlled on oral antidiabetic agents: results from the AT. LANTUS Trial. Diabetologia 2004; 47: Abstract 751.
21. Storms F., Shutler S., Rodriguez J., Gomis R., Davies M. The AT.LANTUS trial investigating treatment algorithms for insulin glargine (LANTUS) therapy: results in subjects with type 1 and type 2 diabetes. Diabetologia 2004; 47: Abstract 910.
22. Davies M., Storms F., Shutler S., Bianchi-Biscay M., Gomis R. Initiation of insulin glargine in type 2 patients with suboptimal glycaemic control on twice-daily premix insulin: results from the AT. LANTUS trial. Diabetologia 2004; 47: Abstract 146.
Рецензия
Для цитирования:
, Эффективность применения инсулина гларгин в условиях реальной клинической практики: результаты наблюдательной программы LAURUS-2. Проблемы Эндокринологии. 2011;57(6):15-20. https://doi.org/10.14341/probl201157615-20
For citation:
Skudaev S.A., Verbovaia N.I. The efficacy of insulin glargine under real clinical practice conditions: results of the LAURUS-2 observational program. Problems of Endocrinology. 2011;57(6):15-20. https://doi.org/10.14341/probl201157615-20
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Послать статью по эл. почте 
.jpg){kind=logo}
